Indeed, PRMT5 inhibitors are in a number of clinical trials, for instance, to treat myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), and solid tumors (including NSCLC) (https://clinicaltrials.gov/). This evidence concerns the gene PRMT5 and acute myeloid leukemia.